You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Uniform length DNA for paired end nextgen sequencing via in vitro packaging
SBC: SCARAB GENOMICS LLC Topic: NIAIDDESCRIPTION (provided by applicant): We have recognized an urgent need for a commercially applicable high throughput way to isolate pure DNA with long and uniform fragment length for nextgen genomic sequencing from precious samples. The advent of nextgen sequencing has driven the cost of DNA sequencing down so that soon it will be feasible to sequence the genomes of individual patients for clinica ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Innate Immune Protection by Clean Genome E. coli
SBC: SCARAB GENOMICS LLC Topic: NIAIDDESCRIPTION (provided by applicant): Complications arising from pathogen infection incur a tremendous societal cost both in morbidity and mortality (as high as 50-60%), as well as in care and treatment estimated in billions of dollars. In susceptible patients, infection induces mis-regulation of the innate immune system that can culminate in systemic inflammation, severe illness and death. The dev ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Engineered Revision of the E. coli Genome for Production
SBC: SCARAB GENOMICS LLC Topic: N/ADESCRIPTION (provided by applicant): E. coli K-12 is well established as a preferred host for commercial production of recombinant DNA products including enzymes, vaccines, metabolites and DNA itself. The complete genome sequence of the E. coli bacterium
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Engineered Revision of E. coli for Production of DNA, Proteins and Metabolites
SBC: SCARAB GENOMICS LLC Topic: N/ADESCRIPTION (provided by applicant): Our goal is to improve the versatility, safety and effectiveness of E. coli as a platform for commercial production of DNA, proteins and metabolites. The natural E. coli genome will be reduced to its essentials by removing unnecessary, detrimental and potentially harmful genes through our Scarless Genome Reduction (SGR) technology. The result will be a robus ...
SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health -
Engineering E. coli for periplasmic protein production
SBC: SCARAB GENOMICS LLC Topic: N/ADESCRIPTION (provided by applicant): Escherichia coli has numerous advantages as a host for the manufacture of recombinant proteins. So far, with a few notable exceptions, it has proven difficult to make disulfide bonded proteins in this host. The few suc
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Engineering E. coli for periplasmic protein production
SBC: SCARAB GENOMICS LLC Topic: N/ADESCRIPTION (provided by applicant): Escherichia coli has numerous advantages as a host for the manufacture of recombinant proteins. So far, with a few notable exceptions, it has proven difficult to make disulfide bonded proteins in this host. The few suc
SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health -
Clean-Genome vaccines against biodefense agents
SBC: SCARAB GENOMICS LLC Topic: N/ADESCRIPTION (provided by applicant): Project description: We propose to develop a new vaccine delivery platform based on a non-pathogenic E. coli with specific safety features. Compared with other bacteria used for vaccines, the E. coli multi-deletion strain (MDS) has been extensively engineered, removing more than 40 large DNA segments totaling 15% of the genome. The deletions are designed to ...
SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health -
Improved bacterial strains for therapeutic DNA production
SBC: SCARAB GENOMICS LLC Topic: N/ADESCRIPTION (provided by applicant): Principal Investigator/Program Director (Last, First, Middle): Blattner, Frederick R. Abstract: The goal of this proposal is to develop methods and strains for manufacturing plasmid DNA of extraordinary purity in very large quantity for therapeutic use. Specifically we propose to use genetic techniques to lower the level of contaminating endotoxin in plasmid DN ...
SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health -
Engineered revision of the E. coli Nissle 1917 Genome
SBC: SCARAB GENOMICS LLC Topic: N/ADESCRIPTION (provided by applicant): The ability of genetically modified probiotic (beneficial) bacteria to deliver therapeutic compounds is a promising new experimental method for delivering fragile and complex bio-molecules without injection. The long-t erm goal of this study is to improve the genetic stability of a probiotic organism for use as a living drug delivery vehicle. Escherichia coli ...
SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
Improved bacterial strains for therapeutic DNA and protein production
SBC: SCARAB GENOMICS LLC Topic: N/ADESCRIPTION (provided by applicant): The goal of this Phase II proposal is to evaluate Scarab Genomics' improved E. coli production strains in real world conditions under which pharmacological grade therapeutic proteins and plasmid DNA are produced. In some cases this will be done in collaboration with contract manufacturers using GMP facilities. Candidate proteins and plasmids will be obtained ...
SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health